- All sections
- C - Chemistry; metallurgy
- C07K - Peptides
- C07K 16/46 - Hybrid immunoglobulins
Patent holdings for IPC class C07K 16/46
Total number of patents in this class: 6920
10-year publication summary
|
426
|
450
|
505
|
584
|
654
|
636
|
600
|
649
|
588
|
176
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 3650 |
226 |
| F. Hoffmann-La Roche AG | 7958 |
175 |
| Hoffmann-La Roche Inc. | 3060 |
158 |
| Amgen Inc. | 3779 |
131 |
| Chugai Seiyaku Kabushiki Kaisha | 1259 |
123 |
| Genentech, Inc. | 3742 |
105 |
| Xencor, Inc. | 403 |
100 |
| Kymab Limited | 229 |
70 |
| Janssen Biotech, Inc. | 1347 |
69 |
| Zymeworks Inc. | 234 |
64 |
| The Regents of the University of California | 18943 |
61 |
| Novartis AG | 11238 |
59 |
| Amgen Research (Munich) GmbH | 236 |
58 |
| Merus N.V. | 185 |
58 |
| Bristol-myers Squibb Company | 5080 |
54 |
| Ablynx N.V. | 377 |
51 |
| MacroGenics, Inc. | 267 |
49 |
| Sanofi | 3836 |
49 |
| Daiichi Sankyo Company, Limited | 1829 |
46 |
| National Research Council of Canada | 1545 |
44 |
| Other owners | 5170 |